Alnylam Pharmaceuticals
ALNY
#632
Rank
C$54.42 B
Marketcap
C$407.61
Share price
-3.59%
Change (1 day)
-2.06%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$5.27

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$5.29. In 2025 the company made an earnings per share (EPS) of C$2.51.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$5.27109.89%
2025C$2.51
2023C-$4.92-62%
2022C-$12.9629.03%
2021C-$10.05-3.36%
2020C-$10.39-8.48%
2019C-$11.367.67%
2018C-$10.5539.74%
2017C-$7.5512.94%
2016C-$6.6838.84%
2015C-$4.81-32.88%
2014C-$7.17259.44%
2013C-$2.00-31.25%
2012C-$2.90

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$9.79 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$3.57-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$59.34 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$11.61-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.02-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.33-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$1.91-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C$0.49-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA